Skip to main content
SpringerLink
Log in
Book cover

Prostate Cancer pp 251–265Cite as

Prostate Cancer Treatment and Quality of Life

  • Chapter

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 175))

Abstract

Prostate cancer is detected today at earlier stages and in younger men than ever before. A lot of men are asymptomatic and also physically and sexually active at diagnosis, and most of them are being treated by curative procedures. These trends have led to increasing numbers of patients undergoing disease management for longer periods of time. For many patients quality of life (QoL) may be just as important as survival. Thus, QoL considerations may well be the critical factor in medical decision-making for most of them. Widespread interest in studying patientcentred outcomes has led to the development of methods for health-related QoL measurements. In fact, many questionnaires have been introduced in clinical practice to assess the impact of QoL in patients (SF-36, CARES, FACT, EORTC QLQ-C30, GRISS, UCLA PCI, PCOS). Herein we evaluate the impact of QoL on patients affected by prostate cancer and treated with watchful waiting, radical prostatectomy, radiotherapy and hormonal therapy; we have also considered the role of supportive care, including the administration of analgesics, antidepressants, corticosteroids, bisphosphonates, antiemetics and stool softeners, together with psychological support. The ultimate goal of QoL research should strongly improve medical care and concretely assist patients and physicians in treatment decision-making.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ferlay J, Bray F, Pisani P, Parkin DM (2001) Cancer incidence, mortality and prevalence worldwide. IARC Cancerbase, 5th edn

    Google Scholar 

  2. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics. CA Cancer J Clin 52:23–47

    PubMed  Google Scholar 

  3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30

    PubMed  Google Scholar 

  4. Moul JW, Wu H, Sun L, mcLeod DG, amling c, Lance R, et al (2002) epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defence Center for Prostate Disease Research national database. Surgery 132:213–219

    PubMed  Google Scholar 

  5. D’Amico AV, Whittington R, Malkowicz SB, Blank K, Broderick GA, et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974

    PubMed  CAS  Google Scholar 

  6. Altwein J, Ekman P, Barry M, Bierman C, Carlsson P, Fossa S, et al (1997) How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium. Urology 49(4A suppl):66–76

    PubMed  CAS  Google Scholar 

  7. Fayers PM, Jones DR (1983) Measuring and analysing quality of life in cancer clinical trials: a review. Stat Med 2:429–446

    PubMed  CAS  Google Scholar 

  8. Sadura A, Pater J, Osoba D, Levine M, Palmer M, Bennett K (1992) Quality of life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst 84:1023–1026

    PubMed  CAS  Google Scholar 

  9. Fossa SD (1994) Quality of life after palliative radiotherapy in patients with hormone-resistant prostate cancer: single institution experience. Br J Urol 74:345–351

    PubMed  CAS  Google Scholar 

  10. WHO (1948) Constitution of the World Health Organization, basic documents. WHO, Geneva

    Google Scholar 

  11. Fossa SD, Hjermstad MJ, Mork IH, Hjortdahl P (1996) Does the service at a large oncologic outpatient clinic satisfy the patients’ perceived need? Int J Health Care Qual Assur 9:24–29

    PubMed  CAS  Google Scholar 

  12. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al (1995) Quality of life outcomes in men treated for localized prostate cancer. JAMA 273:129–135

    PubMed  CAS  Google Scholar 

  13. Litwin MS (1995) How to measure survey reliability and validity. Sage Publications, Thousand Oaks

    Google Scholar 

  14. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483

    PubMed  Google Scholar 

  15. Litwin MS, Lubek DP, Stoddard ML, Pasta DJ, Flanders SC, Henning JM (2001) Quality of life before death for men with prostate cancer: results from the CaPSURE database. J Urol 165:871–875

    PubMed  CAS  Google Scholar 

  16. Eton DT, Lepore SJ, Helgeson VS (2001) Early quality of life in patients with localized prostate carcinoma: an examination of treatment related, demographic, and psychological factors. Cancer 92:1451–1459

    PubMed  CAS  Google Scholar 

  17. Janda M, Gerstner N, Obermair A, Fuerst A, Wachter S, Dieckman K, et al (2000) Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer 89:1322–1328

    PubMed  CAS  Google Scholar 

  18. Borghede G, Sullivan M (1996) Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30. Qual Life Res 5:212–222

    PubMed  CAS  Google Scholar 

  19. Borghede G, Karlsson J, Sullivan M (1997) Quality of life in patients with prostatic cancer: results from a Swedish population study. J Urol 158:1477–1485

    PubMed  CAS  Google Scholar 

  20. Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware Jr JE (1997) Health-related quality of life among patients with metastatic prostate cancer. Urology 49:207–216

    PubMed  CAS  Google Scholar 

  21. Rust J, Golombok S (1985) The Golombok-Rust Inventory of Sexual Satisfaction (GRISS). Br J Clin Psychol 24:63–64

    PubMed  Google Scholar 

  22. Iversen P (1999) Quality of life issues relating to endocrine treatment options. Eur Urol 36(suppl 2):20–26

    PubMed  Google Scholar 

  23. Iversen P (2001) Quality of life issues for patients with prostate cancer. J Urol 166:2291–2292

    PubMed  CAS  Google Scholar 

  24. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ (1997) Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50:920–928

    PubMed  CAS  Google Scholar 

  25. Lee WR, Hall MC, McQuellon RP, Case LD, Mc-Cullough DL (2001) A prospective quality of life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 51:614–623

    PubMed  CAS  Google Scholar 

  26. Johnstone PA, Gray C, Powell CR (2000) Quality of life in T1-3 N0 prostate cancer patients treated with radiation therapy with minimum 10-years follow up. Int J Radiat oncol Biol Phys 46:833–838

    PubMed  CAS  Google Scholar 

  27. Lubeck DP, Litwin MS, Henning JM, Carroll PR (1997) Measurement of health-related quality of life in men with prostate cancer: the CaPSURE database. Qual Life Res 6:385–392

    PubMed  CAS  Google Scholar 

  28. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford Jl, Hamilton AS, et al (2001) Quality of life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 19:3750–3757

    PubMed  CAS  Google Scholar 

  29. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, et al (2002) Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 94:430–437

    PubMed  Google Scholar 

  30. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG (2000) Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56:899–905

    PubMed  CAS  Google Scholar 

  31. Tyrrell C (1999) Gynaecomastia: aetiology and treatment options. Prostate Cancer Prostatic Dis 2:167–171

    PubMed  Google Scholar 

  32. Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G (1996) Waning sexual function the most important disease specific distress for patients with prostate cancer. Br J Cancer 73:1417

    PubMed  CAS  Google Scholar 

  33. Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R (1991) Sex or survival: tradeoffs between quality and quantity of life. J Clin Oncol 9:328–334

    PubMed  CAS  Google Scholar 

  34. Mazur DJ, Hickman DH (1993) Patient preferences: survival versus quality of life considerations. J Gen Intern Med 8:374–377

    PubMed  CAS  Google Scholar 

  35. Jonler M, Nielsen OS, Wolf H (1998) Urinary symptoms, potency, and quality of life in paients with localized prostate cancer followed up with deferred treatment. Urology 52:1055–1062

    PubMed  CAS  Google Scholar 

  36. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al (1995) Quality of life outcomes in men treated for localized prostate cancer. JAMA 273:129

    PubMed  CAS  Google Scholar 

  37. Schapira MM, Lawrence WF, Katz DA, McAuliffe TL, Nattinger AB (2001) Effect of treatment on quality of life among men with clinically localized prostate cancer. Med Care 39:243

    PubMed  CAS  Google Scholar 

  38. Derksen JE, Kshirsagar AV, Mohler JL (2002) Psychological consequences of observation versus radical prostatectomy for clinically localized prostate cancer three and ten years later. J Urol 167:349

    Google Scholar 

  39. Siegel T, Moul JW, Spevak M, Alword WG, Costabile RA (2001) The development of erectile dysfunction in men treated for prostate cancer. J Urol 165:430–435

    PubMed  CAS  Google Scholar 

  40. Dillioglugil O, Leibman BD, Leibman NS, Kattan MW, Rosas AL, Scardino PT (1997) Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol 157:1760

    PubMed  CAS  Google Scholar 

  41. Lu-Yao GL, Albertsen P, Warren J, Yao SL (1999) Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy—a population-based study. Urology 54:301

    PubMed  CAS  Google Scholar 

  42. Goad JR, Eastham JA, Fitzgarald KB, Kattan MW, Collini MP, Yawn DH, et al (1995) radical retropubic prostatectomy: limited benefit of autologous blood donation. J Urol 154:2103

    PubMed  CAS  Google Scholar 

  43. Eastham JA, Goad JR, Rogers E, Ohori M, Kattan MW, Boone TB, et al (1996) Risk factors for urinary incontinence after radical prostatectomy. J Urol 156:1707

    PubMed  CAS  Google Scholar 

  44. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT (1995) Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154:1818

    PubMed  CAS  Google Scholar 

  45. Scardino PT (2000) The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc 111:201

    CAS  Google Scholar 

  46. Guillonneau B, Rozet F, cathelineau X, Lay F, Barret E, Doublet JD, et al (2002) Perioperative complications of laparoscopic radical prostatectomy: the Montsouris 3-year experience. J Urol 167:51

    PubMed  Google Scholar 

  47. Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, et al (1999) Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 91:1719

    PubMed  CAS  Google Scholar 

  48. Tomschi W, Suster G, Holtl W (1998) Bladder neck strictures after radical retropubic prostatectomy: still an unsolved problem. Br J Urol 81:823

    PubMed  CAS  Google Scholar 

  49. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, et al (2000) Health outcomes after radical prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92:1582

    PubMed  CAS  Google Scholar 

  50. Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson JH, Bin L (1996) Outcomes of external beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology and end results areas. J Clin Oncol 14:2258–2265

    PubMed  Google Scholar 

  51. Hanlon AL, Watkins Bruner D, Peter R, Hanks GE (2001) Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 49:51

    PubMed  CAS  Google Scholar 

  52. Roach M, Lew JD, Lawton C, Hsu IC, Machtay M, Seider MJ, et al (2001) A phase III trial comparing whole-pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total antigen suppression: preliminary analysis of RTOG 94-13. Int J Radiat Oncol Biol Phys 51:5

    Google Scholar 

  53. Talcott JA, Clark JA, Starck PC, Mitchell SP (2001) Long term treatment related conplications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 166:494

    PubMed  CAS  Google Scholar 

  54. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation therapy Oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346

    PubMed  CAS  Google Scholar 

  55. Pavy JJ, Denekamp J, Letscher J, et al (1995) Late effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys 31:1043–1049

    PubMed  CAS  Google Scholar 

  56. Hanlon AL, Schultheiss TE, Hunt MA, et al (1997) Chic rectal bleeding after high dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int J Radiat Oncol Biol Phys 38:59–63

    PubMed  CAS  Google Scholar 

  57. Reference deleted in proof

    Google Scholar 

  58. Reference deleted in proof

    Google Scholar 

  59. Storey MR, pollack A, Zagars G, et al (2000) Complications from radiotherapy dose-escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48:635–642

    PubMed  CAS  Google Scholar 

  60. Schultheiss TE, Lee WR, Hunt MA, et al (1997) Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 37:3–11

    PubMed  CAS  Google Scholar 

  61. Incrocci L, Slob AK, Levendag PC, et al (2002) Sexual (dys)function after radiotherapy for prostate cancer: a review. Int J Radiat Oncol Biol Phys 52:681–693

    PubMed  Google Scholar 

  62. Beckendorf V, Hay M, Rozan R, et al (1996) Changes in sexual dysfunction after radiotherapy treatment of prostate cancer. Br J Urol 77:118–123

    PubMed  CAS  Google Scholar 

  63. Rosen RC, Riley A, Wagner G, et al (1997) The International Index for Erectile Function (IIEF). A multidimensional scale for assessment of erectile function. Urology 49:822–830

    PubMed  CAS  Google Scholar 

  64. Merrick GS, Butler WM, Galbreath RW, et al (2002) Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 52:893–902

    PubMed  Google Scholar 

  65. Beard CJ, Propert KJ, Rieker PP, et al (1997) Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study. J Clin Oncol 15:223–229

    PubMed  CAS  Google Scholar 

  66. Zelefsky MJ, Eid JF (1998) Elucidating the etiology of erectile dysfunction after definitive therapy for prostate cancer. Int J Radiat Oncol Biol Phys 40:129–133

    PubMed  CAS  Google Scholar 

  67. Fish BM, Pickett B, Weinberg V, et al (2001) Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer. Urology 57:955–959

    Google Scholar 

  68. Madalinska JB, Essink-Bot M, de Koning HJ, et al (2001) Health-related quality of life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 19:1619–1628

    PubMed  CAS  Google Scholar 

  69. Talcott JA, Rieker P, Clark JA, et al (1998) Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 16:275–283

    PubMed  CAS  Google Scholar 

  70. Emami B, Lyman J, Brown A, et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122

    PubMed  CAS  Google Scholar 

  71. Perez CA, Michalski JM, Purdy JA, et al (2000) Three-dimensional conformal therapy or standard irradiation in localized carcinoma of the prostate: preliminary results of a nonrandomized comparison. Int J Radiat Oncol Biol Phys 47:629–637

    PubMed  CAS  Google Scholar 

  72. Sandler HM, Perez-Tamayo C, Ten Haken RK, et al (1992) Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformal therapy. Radiother Oncol 23:53–54

    PubMed  CAS  Google Scholar 

  73. Zelefsky MJ, Fuks Z, Hunt M, Lee Hj, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, leibel Sa (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166:876–881

    PubMed  CAS  Google Scholar 

  74. Nuting CM, Convery DJ, Cosgrove VP, et al (2000) Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients wiyh prostate cancer. Int J Radiat Oncol Biol Phys 48:649–656

    Google Scholar 

  75. International Commission on Radiation Units and Measurements (1993) Prescribing, recording and reporting photon beam therapy. ICRU report 50. ICRU, Bethesda

    Google Scholar 

  76. Brandeis JM, Litwin MS, Burnison CM, Reiter RE (2000) Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol 163:851–857

    PubMed  CAS  Google Scholar 

  77. Davis JW, Kuban DA, Lynch DF, Schellhammer PF (2001) Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 166:947–952

    PubMed  CAS  Google Scholar 

  78. Bacon CG, Giovannucci E, Testa M, Kawakhi I (2001) The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 166:1804–1810

    PubMed  CAS  Google Scholar 

  79. Wei JT, Dunn RL, Sandler HM, et al (2002) Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20:557–566

    PubMed  Google Scholar 

  80. Reference deleted in proof

    Google Scholar 

  81. Egawa S, Shimura S, Irie A, et al (2001) toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Jpn J Clin Oncol 31:541–547

    PubMed  CAS  Google Scholar 

  82. Herr HW, Kornblith AB, Ofman U (1993) A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 71:1143–1150

    PubMed  CAS  Google Scholar 

  83. Herr HW, O’Sullivan M (2000) Quality of life of asymptomatic men with non metastatic prostate cencer on androgen deprivation therapy. J Urol 163:1743–1746

    PubMed  CAS  Google Scholar 

  84. Migliari R, Muscas G, Murru M, Verdacchi T, De Benedetto G, De Angelis M (1999) Antiandrogen: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Arch Ital Urol Androl 71:293–302

    PubMed  CAS  Google Scholar 

  85. McLeod DG (1997) Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 2:18–27

    PubMed  CAS  Google Scholar 

  86. Wysowski DK, Fourcroy JL (1996) Flutamide hepatotoxicity. J Urol 155:209–212

    PubMed  CAS  Google Scholar 

  87. Cleary PD, morrisey G, oster G (1999) Healthrelated quality of life in patients with advanced prostate cancer, a multinational, perspective. Qual Life Res 4:207–220

    Google Scholar 

  88. Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K, Cockshott ID (1998) Casodex 10–20 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from 3 phase II dose-ranging studies. Casodex Study Group. Eur urol 33:39–53

    PubMed  CAS  Google Scholar 

  89. Wirth M, Tyrrell C, Wallace M, Delaere P, Sanchez-Chapado M, Ramon J, Hetherington J, Pina F, Heynes CF, Borchers TM, Morris T, Stone A (2001) Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces risk of disease progression. Urology 58:146–151

    PubMed  CAS  Google Scholar 

  90. See WA, McLeod D, Iversen P, Wirth M (2001) The bicalutamide Early Prostate Cancer Program. Demography. Urol Oncol 6:43–47

    PubMed  Google Scholar 

  91. See W, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, et al (2002) Bicalutamide (“Casodex”) 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostae cancer: first analysis of the Early Prostate Cancer Program. J Urol 168:429–435

    PubMed  CAS  Google Scholar 

  92. Prezioso D, Piccirillo G, Galasso R, Altieri V, Mirone V, Lotti T (2004) Gynaecomastia due to hormone therapy for advanced prostate cancer: a report of ten surgically treated cases and a review of treatment options. Tumori 90:410–415

    PubMed  Google Scholar 

  93. Reference deleted in proof

    Google Scholar 

  94. Da Silva FC, Fossa SD, Aaronson NK, Serouti S, Denis L, Casselman J, Whelan P, Hetherington J, Fava C, et al (1996) The quality of life with newly diagnosed M1 prostate cancer: experince with EORTC clinical trial 30853. Eur J Cancer 32:72–77

    Google Scholar 

  95. Blue Cross Blue Shield Association Tecnology Evaqluation Center (1999) Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. (Publication 99-E011) US Department of Health and Human Services, Agency for Healthcare Policy and Research

    Google Scholar 

  96. Moinpour CM, Savage MJ, Troxel A, Lovato LC, Eisenberger M, Veith RW, Higgins B, Skeel R, Yee M, Blumenstein BA, Crawford ED, Meyskens FL (1998) Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 90:1537–1544

    PubMed  CAS  Google Scholar 

  97. Cassileth BR, Soloway MS, Viogelzang NJ, Chou JM, Schelhammer PD, Seidmon EJ, et al (1992) Quality of life and psychosocial status in stage D prostate cancer. Qual Life Res 1:323–330

    PubMed  CAS  Google Scholar 

  98. Smith MR, MecGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS (2001) Low bone mineral density in hormone naïve men with prostate carcinoma. Cancer 91:2238–2245

    PubMed  CAS  Google Scholar 

  99. Smith MR, MecGovern FJ, Zietman AL (2001) Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 345:948–955

    PubMed  CAS  Google Scholar 

  100. Lipton A, Small E, Saad F (2002) The new bisphosphonate, zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastich lesions: a comparison to pamidronate. Cancer Invest 20:45–54

    PubMed  CAS  Google Scholar 

  101. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468

    PubMed  CAS  Google Scholar 

  102. Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality of life benefict in chemotherapy patients treated epoetin alpha is independed of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3421–3425

    Google Scholar 

  103. Payne R (1993) Pain management in the patient with prostate cancer. Cancer 71:1131–1137

    PubMed  CAS  Google Scholar 

  104. Twycross RG (1994) The fight against cancer pain. Ann Oncol 5:111–112

    PubMed  CAS  Google Scholar 

  105. Body JJ, Borkowski A, Cleeren A, Bijvoet OL (1986) Treatment of malignancy associated hypercalcemia with intravenous amino-hydroxypropylidene disphosphonate. J Clin Oncol 4:1177–1183

    PubMed  CAS  Google Scholar 

  106. Saad F (2002) Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 1:145–152

    PubMed  CAS  Google Scholar 

  107. Tubaro A (2004) Zoledronic acid: breaking new ground in prostate and renal cancer. Eur Urol Suppl 3:1–2

    Google Scholar 

  108. Crawford ED (2004) Skeletal complications in men with prostate cancer: effects on quality of life outcomes throughout the continuum of care. Eur Urol Suppl 3:10–15

    Google Scholar 

  109. Saad F (2004) Preventing vone complications in patients with prostate cancer: the emerging role of zoledronic acid. Eur Urol Suppl 3:25–33

    CAS  Google Scholar 

  110. Major PP, Cook RJ (2004) Clinical end points for assessing bisphosphonate efficacy in the prevention of skeletal complications of bone metastates. Eur Urol Suppl 3:34–39

    CAS  Google Scholar 

  111. Saad F, Gleason D, Murray R, Venner P, Tchekmedyian NS, Lacombe L, et al (2003) Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone (abstr 1472). Presented at American Urological Association Annual Meeting 26 April–1 May, Chicago. AUA

    Google Scholar 

  112. Saad F, Gleason D, Murray R, Venner P, Goas JA, Chen BL et al (2003) Long term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone (abstr 1472). Presented at American Urological Association Annual Meeting 26 April–1 May, Chicago. AUA

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Naples “Federico II”, Via S. Pansini 5, 80123, Naples, Italy

    Domenico Prezioso MD, Raffaele Galasso MD, Mario Di Martino MD & Gennaro Iapicca MD

Authors
  1. Domenico Prezioso MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raffaele Galasso MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mario Di Martino MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gennaro Iapicca MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, 52621, Israel

    Jacob Ramon MD

  2. Lange Gasthuisstraat 35-37, 2000, Antwerp, Belgium

    Louis J. Denis MD, FACS (Director Oncology Centre Antwerp Secretary Europa Uomo) (Director Oncology Centre Antwerp Secretary Europa Uomo)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Prezioso, D., Galasso, R., Di Martino, M., Iapicca, G. (2007). Prostate Cancer Treatment and Quality of Life. In: Ramon, J., Denis, L.J. (eds) Prostate Cancer. Recent Results in Cancer Research, vol 175. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-40901-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-40901-4_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40897-0

  • Online ISBN: 978-3-540-40901-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation